MCID: LNG003
MIFTS: 36

Lung Carcinoma in Situ

Categories: Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Lung Carcinoma in Situ

MalaCards integrated aliases for Lung Carcinoma in Situ:

Name: Lung Carcinoma in Situ 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:8800
ICD9CM 34 231.2
SNOMED-CT 67 189262006
ICD10 32 D02.2
UMLS 70 C0154071

Summaries for Lung Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the lung.

MalaCards based summary : Lung Carcinoma in Situ is related to lung squamous cell carcinoma and in situ carcinoma. An important gene associated with Lung Carcinoma in Situ is OR9A4 (Olfactory Receptor Family 9 Subfamily A Member 4), and among its related pathways/superpathways are Pathways in cancer and 4-1BB Pathway. Affiliated tissues include lung, and related phenotype is neoplasm.

Related Diseases for Lung Carcinoma in Situ

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Related Disease Score Top Affiliating Genes
1 lung squamous cell carcinoma 30.0 KRAS HRAS EGFR ALK
2 in situ carcinoma 29.8 HRAS EGFR EGF
3 pulmonary adenocarcinoma in situ 29.2 SFTPC NKX2-1 MIR4803 MIR4791 MIR3153 KRAS
4 hepatic flexure cancer 10.4 KRAS HRAS
5 trachea carcinoma in situ 10.4 KRAS HRAS
6 signet ring basal cell carcinoma 10.4 KRAS HRAS
7 cobblestone retinal degeneration 10.4 KRAS HRAS
8 immature teratoma of ovary 10.4 KRAS HRAS
9 pancreatic signet ring cell adenocarcinoma 10.4 KRAS HRAS
10 descending colon cancer 10.4 KRAS HRAS
11 ampulla of vater benign neoplasm 10.4 KRAS HRAS
12 transverse colon cancer 10.4 KRAS HRAS
13 periampullary adenoma 10.4 KRAS HRAS
14 bone giant cell sarcoma 10.4 KRAS HRAS
15 appendiceal neoplasm 10.4 KRAS HRAS
16 gallbladder benign neoplasm 10.4 KRAS HRAS
17 appendix adenocarcinoma 10.3 KRAS HRAS
18 wolffian duct adenocarcinoma 10.3 KRAS HRAS
19 noonan syndrome-like disorder with loose anagen hair 1 10.3 KRAS HRAS
20 noonan syndrome-like disorder with loose anagen hair 10.3 KRAS HRAS
21 myh-associated polyposis 10.3 KRAS HRAS
22 ascending colon cancer 10.3 KRAS HRAS
23 biliary tract benign neoplasm 10.3 KRAS HRAS
24 ovarian mucinous neoplasm 10.3 KRAS HRAS
25 malignant exocrine pancreas neoplasm 10.3 KRAS HRAS
26 pancreatic acinar cell adenocarcinoma 10.3 KRAS HRAS
27 appendix disease 10.3 KRAS HRAS
28 bile duct cysts 10.3 KRAS HRAS
29 small intestine adenocarcinoma 10.3 KRAS HRAS
30 keratinizing squamous cell carcinoma 10.3 NKX2-1 EGFR
31 appendix cancer 10.3 KRAS HRAS
32 duodenum adenocarcinoma 10.3 KRAS HRAS
33 core binding factor acute myeloid leukemia 10.3 KRAS HRAS
34 struma ovarii 10.3 NKX2-1 KRAS
35 oculoectodermal syndrome 10.3 KRAS HRAS
36 acneiform dermatitis 10.3 KRAS HRAS EGFR
37 ethmoid sinus adenocarcinoma 10.3 KRAS HRAS EGFR
38 anus cancer 10.3 KRAS HRAS EGFR
39 skin papilloma 10.3 KRAS HRAS EGFR
40 uterine body mixed cancer 10.3 KRAS HRAS EGFR
41 mixed cell type cancer 10.3 KRAS HRAS EGFR
42 rectum adenocarcinoma 10.3 KRAS HRAS EGFR
43 ovarian cystadenocarcinoma 10.3 KRAS HRAS EGFR
44 uterine corpus cancer 10.3 KRAS HRAS EGFR
45 colonic benign neoplasm 10.3 KRAS HRAS EGFR
46 exanthem 10.3 KRAS HRAS EGFR
47 lymphangitis 10.3 NKX2-1 ALK
48 ovary adenocarcinoma 10.2 KRAS HRAS EGFR
49 penile cancer 10.2 KRAS HRAS EGFR
50 pulmonary blastoma 10.2 NKX2-1 KRAS EGFR

Graphical network of the top 20 diseases related to Lung Carcinoma in Situ:



Diseases related to Lung Carcinoma in Situ

Symptoms & Phenotypes for Lung Carcinoma in Situ

MGI Mouse Phenotypes related to Lung Carcinoma in Situ:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AHRR ALK EGFR HRAS KRAS NKX2-1

Drugs & Therapeutics for Lung Carcinoma in Situ

Search Clinical Trials , NIH Clinical Center for Lung Carcinoma in Situ

Genetic Tests for Lung Carcinoma in Situ

Anatomical Context for Lung Carcinoma in Situ

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Carcinoma in Situ:

19
Lung

MalaCards organs/tissues related to Lung Carcinoma in Situ:

40
Lung

Publications for Lung Carcinoma in Situ

Articles related to Lung Carcinoma in Situ:

# Title Authors PMID Year
1
Role of bronchoscopy in management of central squamous cell lung carcinoma in situ. 61
31516900 2019
2
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. 61
30664780 2019
3
Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. 61
26725182 2016
4
miR-101 DNA copy loss is a prominent subtype specific event in lung cancer. 61
21849855 2011
5
Diagnosis and treatment of early lung cancer: as it stands today. 61
16088482 2004
6
Endoscopic treatment of early-stage lung cancer. 61
10740659 2000
7
[The prognostic significance of the direct effect in the conservative treatment of small-cell lung cancer]. 61
1658530 1991

Variations for Lung Carcinoma in Situ

Cosmic variations for Lung Carcinoma in Situ:

9 (show top 50) (show all 1540)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 6
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 6
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 6
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 6
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 6
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 6
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 6
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 6
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 6
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 6
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 6
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 6
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 6
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 6
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 6
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 6
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 6
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 6
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 6
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 6
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 6
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 6
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 6
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 6
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 6
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 6
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 6
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 6
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 6
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 6
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 6
42 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 6
43 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 6
44 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 6
45 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 6
46 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 6
47 COSM99795256 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 6
48 COSM143996084 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1620C>G p.F540L 19:4947122-4947122 6
49 COSM143964403 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1428C>G p.F476L 19:4947122-4947122 6
50 COSM145430147 UHRF1 lung,NS,carcinoma,undifferentiated carcinoma c.1467C>G p.F489L 19:4947122-4947122 6

Expression for Lung Carcinoma in Situ

Search GEO for disease gene expression data for Lung Carcinoma in Situ.

Pathways for Lung Carcinoma in Situ

Pathways related to Lung Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1 12.71 KRAS HRAS EML4 EGFR EGF ALK
2
Show member pathways
12.56 KRAS HRAS EGFR EGF
3 12.54 KRAS HRAS EGFR EGF
4
Show member pathways
12.51 KRAS HRAS EGFR EGF
5
Show member pathways
12.48 KRAS HRAS EML4 EGFR EGF ALK
6
Show member pathways
12.4 KRAS HRAS EGFR EGF
7
Show member pathways
12.34 KRAS HRAS EML4 EGFR EGF ALK
8
Show member pathways
12.32 KRAS HRAS EGFR EGF
9
Show member pathways
12.32 KRAS HRAS EGFR EGF
10
Show member pathways
12.32 KRAS HRAS EGFR EGF ALK
11
Show member pathways
12.27 KRAS HRAS EGFR EGF
12
Show member pathways
12.22 KRAS HRAS EGFR EGF
13 12.12 KRAS HRAS EGFR EGF
14
Show member pathways
12.06 KRAS HRAS EGFR EGF
15
Show member pathways
12.01 KRAS HRAS EGFR EGF
16
Show member pathways
11.98 KRAS HRAS EGFR EGF
17 11.87 KRAS HRAS EGFR EGF
18
Show member pathways
11.83 KRAS HRAS EGFR EGF
19
Show member pathways
11.74 KRAS HRAS EGFR EGF
20 11.7 KRAS HRAS EGFR EGF
21 11.65 KRAS HRAS EGFR
22 11.64 KRAS HRAS EGFR EGF
23 11.6 KRAS HRAS EGFR EGF
24 11.54 KRAS HRAS EGFR
25
Show member pathways
11.52 HRAS EGFR EGF
26 11.24 KRAS HRAS EGFR AHRR
27 11.23 HRAS EGFR EGF
28 11.2 KRAS HRAS EGFR
29 11.14 KRAS EGFR EGF
30 11.09 KRAS HRAS EGFR EGF
31 10.97 KRAS HRAS
32 10.84 KRAS HRAS EML4 ALK
33 10.76 KRAS HRAS
34 10.69 HRAS EGFR EGF
35
Show member pathways
10.34 KRAS HRAS EGFR EGF
36
Show member pathways
10.19 EGFR EGF

GO Terms for Lung Carcinoma in Situ

Biological processes related to Lung Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.67 KRAS HRAS EGFR EGF
2 liver development GO:0001889 9.5 KRAS HRAS EGFR
3 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.46 EGFR EGF
4 epithelial tube branching involved in lung morphogenesis GO:0060441 9.43 NKX2-1 KRAS
5 regulation of long-term neuronal synaptic plasticity GO:0048169 9.4 KRAS HRAS
6 response to isolation stress GO:0035900 9.26 KRAS HRAS
7 negative regulation of ERBB signaling pathway GO:1901185 9.16 EGFR EGF
8 positive regulation of DNA replication GO:0045740 9.13 HRAS EGFR EGF
9 positive regulation of MAP kinase activity GO:0043406 8.92 KRAS HRAS EGFR EGF

Sources for Lung Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....